Company / Return on Equity (ROE)
Cullinan Therapeutics, Inc. Return on Equity (ROE) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-28.3%
FY2024
5-year range
-33.8% / 20.8%
FY2020-FY2024
Trend
+16.0%
vs FY2023
Sector context
#90 of 190
Health Care
What the data says
Cullinan Therapeutics, Inc. reports negative total equity of -28.3% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-28.3% in FY2024 with a 3-year CAGR of -16.2%.
Declined from 20.8% to -28.3% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -16.2pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#90 of 190 in Health CareTop 47% of 190This company -28.3% Sector average -50.4%
▼
+43.8% above sector average
Key checks
Key Insights
- In FY2024, return on equity (roe) increased 16.0% year-over-year.
- Currently 22.1pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2022.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -28.3% | +16.0% |
| FY2023 | -33.8% | -262.4% |
| FY2022 | 20.8% | +270.5% |
| FY2021 | -12.2% | +52.9% |
| FY2020 | -25.9% | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026